About Ketorol D.T.
- KETOROL D.T. from Dr. Reddy’s is the World’s No. 1 Brand for dental pain relief and is trusted by doctors since the past 25+ years.*
- Available in dispersible formulation with fast action within 10 minutes1 of intake.
- Ketorolac is a light-sensitive molecule and KETOROL D.T. comes in Alu-blister packaging to ensure maximum protection from sunlight.
*Data on file
1. Vadivedlu N, et al. Pain Pract. 2015;15(2):175-193. 2. Sadeghein A, et al. J Endod. 1999;25(4):257-259
Where to Use?
It is used in the short-term management of moderate postoperative pain.
Dosage and administration
- Ketorolac tablets are recommended for short-term use only (up to 7 days) and are not recommended for chronic use.
- Adults: 20 mg once, followed by 10 mg every 6 hrs, not exceeding 40 mg in a day.
- Elderly: A longer dosing interval, e.g. 6-8 hourly, is advisable in the elderly.
- Children: The safety and efficacy profile of ketorolac in paediatric patients <18 years has not been clinically established.
- For patients receiving parenteral ketorolac, and who are converted to ketorolac oral tablets, the total combined daily dose should not exceed 90 mg and the oral component should not exceed 40 mg on the day the change of formulation is made.
Safety Advise
Dosage & administration:
- Adults: 20 mg once followed by 10 mg every 6 hrs.
- Maximum dose: 40 mg
- Maximum Duration: up to 7 days.
- Elderly: longer dosing interval, e.g. 6-8 hourly
Use in specific populations:
The long-term administration of ketorolac tromethamine is not recommended as the incidence of side-effects increases with the duration of treatment.
- Use in Pregnancy and Lactation: Not recommended during pregnancy or lactation.
- Use in Children: Not recommended for use in children under age 16.
- Use in the Elderly: Extra caution and the lowest effective dose should be used.
- Use in Renal, Hepatic & Heart failure patients: Not recommended
What are the Side Effects?
- Renal events: Acute renal failure, flank pain with or without haematuria and/or azotaemia, nephritis, hyponatremia, hyperkalaemia, haemolytic uremic syndrome, urinary retention.
- Hypersensitivity reactions: Bronchospasm, laryngeal oedema, asthma, hypotension, flushing, rash, anaphylaxis, and anaphylactoid reactions.
- Gastrointestinal events: Gastrointestinal haemorrhage, peptic ulceration, gastrointestinal perforation, pancreatitis, melena.
- Hematologic events: Postoperative wound hemorrhage, rarely requiring blood transfusion, thrombocytopenia, epistaxis, leukopenia.
- Central nervous system: Convulsions, hallucinations, hyperkinesia, hearing loss, aseptic meningitis, extrapyramidal symptoms.
- Hepatic events: Hepatitis, liver failure, cholestatic jaundice Cardiovascular: pulmonary edema, hypotension, flushing.
- Dermatology: Lyell's syndrome, Stevens-Johnson syndrome, exfoliative dermatitis, maculopapular rash, urticarial.
Ketorol Vs. NSAIDs
- Ketorolac is predominantly prescribed by dental practitioners for monotherapy in dental pain management, followed by diclofenac and aceclofenac.
- Ketorolac is administered across all phases of dental pain and is the most preferred option among the analgesics (monotherapy/combinations) by dental practitioners.
Shukla K, Kiran Pebbili K, Bhagat SV, Rathod R, Kotak BP. Prospective Evaluation of Dental Practitioners'
Knowledge, Attitude, and Practice Toward Adult Dental Pain Management: A Cross-Sectional Multicenter Study. Cureus. 2024 Mar 2;16(3):e55388. doi: 10.7759/cu reus.55388. PMID: 38562370; PMCID: PMC10984245.
Editor's Pick
Minimally Invasive BPH/LUTS Surgeries: Why Do They Attract More Attention Than Medical Management ?
Minimally Invasive BPH/LUTS Surgeries: Why Do They Attract More Attention Than Medical Management ?
Minimally invasive BPH surgeries vs. medical therapy—watch now!Minimally Invasive BPH/LUTS Surgeries: Why Do They Attract More Attention Than Medical Management ?
What Is the Level of Concords and Discords for BPH Consensus Statements Including IPSS Relevance?
What Is the Level of Concords and Discords for BPH Consensus Statements Including IPSS Relevance?
Immediate Insights: Clinician Debates on BPHWhat Is the Level of Concords and Discords for BPH Consensus Statements Including IPSS Relevance?
When’s the Right Time to Prescribe Alpha Blockers & 5-Alpha Reductase Inhibitor Combination for BPH?
When’s the Right Time to Prescribe Alpha Blockers & 5-Alpha Reductase Inhibitor Combination for BPH?
Unlock the clinical timing of AB + 5-ARI for BPH treatment.When’s the Right Time to Prescribe Alpha Blockers & 5-Alpha Reductase Inhibitor Combination for BPH?
Minimally Invasive BPH/LUTS Surgeries: Are They Worthy of Attention Over Medical Therapy?
Minimally Invasive BPH/LUTS Surgeries: Are They Worthy of Attention Over Medical Therapy?
Minimally invasive BPH surgeries vs. medical therapy—watch now!Minimally Invasive BPH/LUTS Surgeries: Are They Worthy of Attention Over Medical Therapy?
What Patient Queries About Alpha Blockers Do You Encounter While Managing BPH?
What Patient Queries About Alpha Blockers Do You Encounter While Managing BPH?
Daily vs. alternate-day dosing—patients want answers.What Patient Queries About Alpha Blockers Do You Encounter While Managing BPH?
Are All BPH/LUTS Treatments Created Equal, or Is it Time to Consider A More Personalized Approach?
Are All BPH/LUTS Treatments Created Equal, or Is it Time to Consider A More Personalized Approach?
Explore the need for personalized BPH management.Are All BPH/LUTS Treatments Created Equal, or Is it Time to Consider A More Personalized Approach?
Are Your Patients Struggling With Functional Constipation?
Are Your Patients Struggling With Functional Constipation?
Act Now: Patients Struggling With Functional Constipation?Addressing Guilt and Embarrassment in Pediatric Patients with Fecal Incontinence
Addressing Guilt and Embarrassment in Pediatric Patients with Fecal Incontinence
Overcoming Pediatric Fecal Incontinence..PEG vs. Lactulose: Enhancing Defecation Frequency With Fewer Side Effects
PEG vs. Lactulose: Enhancing Defecation Frequency With Fewer Side Effects
Increase Defecation Frequency Now: PEG vs. LactuloseVideos Speakers
Analgesic onset of FA-acetaminophen in a postoperative dental impaction pain model
Analgesic onset of FA-acetaminophen in a postoperative dental impaction pain model
A recent study has shown that fast-acting acetaminophen (FA-acetaminophen) had a quicker onset of action than both commercial acetaminophen caplets (ES-acetaminophen) and commercial ibuprofen liquid-filled gelatin capsules (LG-Ibuprofen). This study findings were published in the journal, Current Medical Research and Opinion.
Two single-center, randomized, inpatient, placebo-controlled, double-blind design clinical trials were carried out utilizing the postoperative dental impaction pain model. Study 1 included 240 subjects, whereas study 2 had 420 subjects. The individuals involved in this study were between the ages of 17 and 50 and were suffering from moderate to severe pain after undergoing the surgical extraction of a minimum of three impacted third molars. The two studies evaluated four different treatment groups: 1,000 mg of FA-acetaminophen, 400 mg of LG-ibuprofen, 1,000 mg of ES-acetaminophen, and a placebo. The double-stopwatch method was used to determine the times to confirm perceptible pain relief (TCPR) and meaningful pain relief (TMPR). Pain intensity and relief were assessed using a 0-10 numerical rating scale for a duration of 6 hours after administering the drug.
The efficacy results demonstrated that all active treatments were statistically superior to the placebo. Within study 1, TCPR was significantly shorter for FA-acetaminophen in comparison to ES-acetaminophen and LG-ibuprofen. Additionally, FA-acetaminophen 1,000 mg showed a significantly shorter TMPR compared to LG-ibuprofen. In both studies 1 and 2, at the 15-minute mark post-administration of the study drug, PID and PAR scores were higher for FA-acetaminophen than LG-ibuprofen.
It can be concluded that FA-acetaminophen demonstrated a faster onset of action in comparison to both ES-acetaminophen and LG-Ibuprofen.
Analgesic onset of FA-acetaminophen in a postoperative dental impaction pain model
Analgesic onset of FA-acetaminophen in a postoperative dental impaction pain model
A recent study has shown that fast-acting acetaminophen (FA-acetaminophen) had a quicker onset of action than both commercial acetaminophen caplets (ES-acetaminophen) and commercial ibuprofen liquid-filled gelatin capsules (LG-Ibuprofen). This study findings were published in the journal, Current Medical Research and Opinion.
Two single-center, randomized, inpatient, placebo-controlled, double-blind design clinical trials were carried out utilizing the postoperative dental impaction pain model. Study 1 included 240 subjects, whereas study 2 had 420 subjects. The individuals involved in this study were between the ages of 17 and 50 and were suffering from moderate to severe pain after undergoing the surgical extraction of a minimum of three impacted third molars. The two studies evaluated four different treatment groups: 1,000 mg of FA-acetaminophen, 400 mg of LG-ibuprofen, 1,000 mg of ES-acetaminophen, and a placebo. The double-stopwatch method was used to determine the times to confirm perceptible pain relief (TCPR) and meaningful pain relief (TMPR). Pain intensity and relief were assessed using a 0-10 numerical rating scale for a duration of 6 hours after administering the drug.
The efficacy results demonstrated that all active treatments were statistically superior to the placebo. Within study 1, TCPR was significantly shorter for FA-acetaminophen in comparison to ES-acetaminophen and LG-ibuprofen. Additionally, FA-acetaminophen 1,000 mg showed a significantly shorter TMPR compared to LG-ibuprofen. In both studies 1 and 2, at the 15-minute mark post-administration of the study drug, PID and PAR scores were higher for FA-acetaminophen than LG-ibuprofen.
It can be concluded that FA-acetaminophen demonstrated a faster onset of action in comparison to both ES-acetaminophen and LG-Ibuprofen.
B-Gn-F plane proves as the most accurate best mandibular midsagittal plane to segment and identify mandible anatomical landmarks
B-Gn-F plane proves as the most accurate best mandibular midsagittal plane to segment and identify mandible anatomical landmarks
According to a recent study, deep learning can segment and identify mandibular midline landmarks with the help of the best mandibular midsagittal plane (MMSP), which is B-Gn-F. This study was published in the European Journal of Medical Research.
This study included 400 participants who were randomly assigned into a training group (n=360) and a validation group (n=40), along with a test group (n=50) comprising normal individuals. PoseNet identified 27 anatomic landmarks from the mandible images from cone-beam computed tomography (CBCT) using the PointRend deep learning mechanism. For the test group, three-dimensional (3D) coordinates were obtained for five central landmarks and two pairs of side landmarks. Using the template mapping technique, every 35 combinations of 3 midline landmarks were screened. For each of the 35 mirror planes, the asymmetry index (AI) was calculated. The top 4 planes having the smallest AIs were compared through volume difference, similarity index, and distance in order to find the plane with the least errors.
At the end of the study, it was found that in 10 ± 1.5 seconds, the mandible was automatically segmented with a 0.98 Dice similarity coefficient. Among the 27 landmarks, the average localization error was 1.04 ± 0.28 mm. The plane created by B (supramentale), Gn (gnathion), and F (mandibular foramen) should be used by MMSP. The average AI grade observed was 1.6. No significant difference was seen in volume or distance, although the similarity index was significantly different.
From the above results, it can be concluded that deep learning may segment and identify mandibular midline landmarks with the help of the best mandibular midsagittal plane (MMSP), which is B-Gn-F.
B-Gn-F plane proves as the most accurate best mandibular midsagittal plane to segment and identify mandible anatomical landmarks
B-Gn-F plane proves as the most accurate best mandibular midsagittal plane to segment and identify mandible anatomical landmarks
According to a recent study, deep learning can segment and identify mandibular midline landmarks with the help of the best mandibular midsagittal plane (MMSP), which is B-Gn-F. This study was published in the European Journal of Medical Research.
This study included 400 participants who were randomly assigned into a training group (n=360) and a validation group (n=40), along with a test group (n=50) comprising normal individuals. PoseNet identified 27 anatomic landmarks from the mandible images from cone-beam computed tomography (CBCT) using the PointRend deep learning mechanism. For the test group, three-dimensional (3D) coordinates were obtained for five central landmarks and two pairs of side landmarks. Using the template mapping technique, every 35 combinations of 3 midline landmarks were screened. For each of the 35 mirror planes, the asymmetry index (AI) was calculated. The top 4 planes having the smallest AIs were compared through volume difference, similarity index, and distance in order to find the plane with the least errors.
At the end of the study, it was found that in 10 ± 1.5 seconds, the mandible was automatically segmented with a 0.98 Dice similarity coefficient. Among the 27 landmarks, the average localization error was 1.04 ± 0.28 mm. The plane created by B (supramentale), Gn (gnathion), and F (mandibular foramen) should be used by MMSP. The average AI grade observed was 1.6. No significant difference was seen in volume or distance, although the similarity index was significantly different.
From the above results, it can be concluded that deep learning may segment and identify mandibular midline landmarks with the help of the best mandibular midsagittal plane (MMSP), which is B-Gn-F.
Evaluation and comparison of the effectiveness of low-level laser therapy and low-intensity pulsed ultrasound in reducing orthodontic pain
Evaluation and comparison of the effectiveness of low-level laser therapy and low-intensity pulsed ultrasound in reducing orthodontic pain
According to a recent study, low-level laser therapy (LLLT) and low-intensity pulsed ultrasound (LIPUS) effectively reduced separation pain when applied in multiple doses during orthodontic treatment. The results of this study were published in the journal, BMC Oral Health.
150 patients were randomly assigned to three groups in this single-blind, randomized controlled trial: the LLLT group, the LIPUS group, and the control group. The first dose of the laser or ultrasound was applied 5 min from the separators' placement, second dose was given after 24 h, and the last dose was administered on both maxillary and mandibular first molars after 48 h. The patients were exposed to the laser for 20 s, using an 810-nm aluminum-gallium-arsenide (AlGaAs) diode laser on continuous mode. For 20 minutes, 1.6 MHz ultrasonic toothbrush treatment was applied (5 minutes for each first molar). The control group was administered the separator without any other intervention. Pain intensity was assessed at several time intervals during the first four days post the separator’s placement, using a Visual Analog Scale (VAS 100 mm).
It was found after assessing 145 patients that a significant difference in pain perception was observed among the three groups after 5 min. Pain level reached its maximum intensity after 24 h. All the assessment time points showed a statistically significant decrease in pain scores for both the laser and the ultrasound groups when compared to the control group. Moreover, the laser and ultrasound group showed no difference between them in terms of reducing the pain scores.
Hence, it can be concluded that LLLT and the LIPUS may effectively reduce the separation pain experienced during orthodontic treatment after the application of multiple doses, without any difference between them.
Evaluation and comparison of the effectiveness of low-level laser therapy and low-intensity pulsed ultrasound in reducing orthodontic pain
Evaluation and comparison of the effectiveness of low-level laser therapy and low-intensity pulsed ultrasound in reducing orthodontic pain
According to a recent study, low-level laser therapy (LLLT) and low-intensity pulsed ultrasound (LIPUS) effectively reduced separation pain when applied in multiple doses during orthodontic treatment. The results of this study were published in the journal, BMC Oral Health.
150 patients were randomly assigned to three groups in this single-blind, randomized controlled trial: the LLLT group, the LIPUS group, and the control group. The first dose of the laser or ultrasound was applied 5 min from the separators' placement, second dose was given after 24 h, and the last dose was administered on both maxillary and mandibular first molars after 48 h. The patients were exposed to the laser for 20 s, using an 810-nm aluminum-gallium-arsenide (AlGaAs) diode laser on continuous mode. For 20 minutes, 1.6 MHz ultrasonic toothbrush treatment was applied (5 minutes for each first molar). The control group was administered the separator without any other intervention. Pain intensity was assessed at several time intervals during the first four days post the separator’s placement, using a Visual Analog Scale (VAS 100 mm).
It was found after assessing 145 patients that a significant difference in pain perception was observed among the three groups after 5 min. Pain level reached its maximum intensity after 24 h. All the assessment time points showed a statistically significant decrease in pain scores for both the laser and the ultrasound groups when compared to the control group. Moreover, the laser and ultrasound group showed no difference between them in terms of reducing the pain scores.
Hence, it can be concluded that LLLT and the LIPUS may effectively reduce the separation pain experienced during orthodontic treatment after the application of multiple doses, without any difference between them.
Impact of silver diamine fluoride and nano silver fluoride on the oral health-related quality of life of children
Impact of silver diamine fluoride and nano silver fluoride on the oral health-related quality of life of children
According to a recent study, Silver diamine fluoride (SDF) and Nano Silver Fluoride (NSF) after 6 months exhibited significant enhancements in children's Oral Health-Related Quality of Life (OHRQoL). It was observed that NSF had a significantly superior impact on OHRQoL compared to SDF. This study’s results were published in the Journal of dentistry.
This study involved 360 children under the age of 4, each having at least one active lesion with an International Caries Detection and Assessment System (ICDAS) score of ≥3. They were randomly divided into two groups: one receiving NSF at the beginning, and the other receiving SDF at the start and after 6 months. The Oral Health-Related Quality of Life (OHRQoL) was assessed using the Arabic version of the Early Childhood Oral Health Impact Scale (A-ECOHIS). Additionally, group comparisons were made using the chi-square test, and the impact of the intervention on OHRQoL was analyzed through multiple linear regression.
In the bivariate analysis and regression analysis (B= -5.02) with confounder adjustments, it was observed that NSF exhibited significantly lower A-ECOHIS scores compared to SDF after a period of 6 months. Both groups showed significant decreases in the A-ECOHIS domain and total scores, except for the social interaction domain in the SDF group.
The above study demonstrated that after a 6-month period, both NSF and SDF led to a significant improvement in children's OHRQoL. However, NSF had a notably greater impact on OHRQoL compared to SDF.
Impact of silver diamine fluoride and nano silver fluoride on the oral health-related quality of life of children
Impact of silver diamine fluoride and nano silver fluoride on the oral health-related quality of life of children
According to a recent study, Silver diamine fluoride (SDF) and Nano Silver Fluoride (NSF) after 6 months exhibited significant enhancements in children's Oral Health-Related Quality of Life (OHRQoL). It was observed that NSF had a significantly superior impact on OHRQoL compared to SDF. This study’s results were published in the Journal of dentistry.
This study involved 360 children under the age of 4, each having at least one active lesion with an International Caries Detection and Assessment System (ICDAS) score of ≥3. They were randomly divided into two groups: one receiving NSF at the beginning, and the other receiving SDF at the start and after 6 months. The Oral Health-Related Quality of Life (OHRQoL) was assessed using the Arabic version of the Early Childhood Oral Health Impact Scale (A-ECOHIS). Additionally, group comparisons were made using the chi-square test, and the impact of the intervention on OHRQoL was analyzed through multiple linear regression.
In the bivariate analysis and regression analysis (B= -5.02) with confounder adjustments, it was observed that NSF exhibited significantly lower A-ECOHIS scores compared to SDF after a period of 6 months. Both groups showed significant decreases in the A-ECOHIS domain and total scores, except for the social interaction domain in the SDF group.
The above study demonstrated that after a 6-month period, both NSF and SDF led to a significant improvement in children's OHRQoL. However, NSF had a notably greater impact on OHRQoL compared to SDF.
The efficacy and safety of a toothpaste containing bioactive glass-ceramic in treating dentinal hypersensitivity
The efficacy and safety of a toothpaste containing bioactive glass-ceramic in treating dentinal hypersensitivity
According to a recent study, the bioactive glass-ceramic (HX-BGC) and NovaMin toothpaste exhibited more significant effects in addressing dentinal hypersensitivity when compared to the negative control group. No adverse reactions associated with the experimental toothpastes were noted. This study’s research findings were published in the Journal of Dentistry.
In this single-center, randomized, double-blind study, participants were randomly allocated to use one of the HX-BGC, NovaMin, or negative control toothpastes. Follow-up examinations were conducted immediately after a single use and at 2 weeks, 4 weeks , and 6 weeks. Schiff and Yeaple indices were used for intra-group and inter-group comparisons. The safety of the experimental toothpastes was evaluated through participant feedback and oral soft tissue examinations.
There was an increase in Yeaple indices across all groups, with significant differences noted between the HX-BGC group and the other two groups after a continuous 2-week period of use. Schiff indices decreased in all groups, with the NovaMin group demonstrating significant differences when compared to the negative control group. Significant improvement was observed in both the HX-BGC group and the NovaMin group by weeks 4 and 6 compared to the negative control group in both indices. The HX-BGC group exhibited better results in the Yeaple index compared to the NovaMin group. Additionally, no serious adverse reactions related to the toothpastes were reported or observed among the participants.
The above study confirmed the efficacy of HX-BGC in treating dentinal hypersensitivity and supported the clinical use of dentifrices formulated with HX-BGC. Both the HX-BGC and NovaMin toothpaste groups exhibited significantly greater efficacy in managing dentinal hypersensitivity compared to the negative control group. There were no adverse reactions reported in relation to the experimental toothpastes.
The efficacy and safety of a toothpaste containing bioactive glass-ceramic in treating dentinal hypersensitivity
The efficacy and safety of a toothpaste containing bioactive glass-ceramic in treating dentinal hypersensitivity
According to a recent study, the bioactive glass-ceramic (HX-BGC) and NovaMin toothpaste exhibited more significant effects in addressing dentinal hypersensitivity when compared to the negative control group. No adverse reactions associated with the experimental toothpastes were noted. This study’s research findings were published in the Journal of Dentistry.
In this single-center, randomized, double-blind study, participants were randomly allocated to use one of the HX-BGC, NovaMin, or negative control toothpastes. Follow-up examinations were conducted immediately after a single use and at 2 weeks, 4 weeks , and 6 weeks. Schiff and Yeaple indices were used for intra-group and inter-group comparisons. The safety of the experimental toothpastes was evaluated through participant feedback and oral soft tissue examinations.
There was an increase in Yeaple indices across all groups, with significant differences noted between the HX-BGC group and the other two groups after a continuous 2-week period of use. Schiff indices decreased in all groups, with the NovaMin group demonstrating significant differences when compared to the negative control group. Significant improvement was observed in both the HX-BGC group and the NovaMin group by weeks 4 and 6 compared to the negative control group in both indices. The HX-BGC group exhibited better results in the Yeaple index compared to the NovaMin group. Additionally, no serious adverse reactions related to the toothpastes were reported or observed among the participants.
The above study confirmed the efficacy of HX-BGC in treating dentinal hypersensitivity and supported the clinical use of dentifrices formulated with HX-BGC. Both the HX-BGC and NovaMin toothpaste groups exhibited significantly greater efficacy in managing dentinal hypersensitivity compared to the negative control group. There were no adverse reactions reported in relation to the experimental toothpastes.
How would you rate this Medshorts
Thank you !
Your rating has been recorded.
Videos Speakers
Ketorol-DT 1
Ketorol-DT 1, Dental, Dental & Oral Health, Dentist, Docvidya, Brands
Below fields are needed for webinar purpose.